Coley initiated by Leerink Swann at outperform

Coley Pharmaceutical Group Inc. coverage was initiated by Leerink Swann analyst William Tanner at an outperform rating. Leerink Swann believes Coley has a compelling technology platform using toll-like receptors to activate the immune system, validated by partnership agreements with Pfizer and Sanofi-Aventis. Coley shares Monday were up $0.19, or 1.12%, at $17.19 on volume of 141,230 shares versus the three-month running average of 371,759 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.